MicroCore Bio: The product Sidaibenzamine has been included in the national medical insurance catalog for routine class B management.

Weix Bio announced that on December 7, 2025, the company's product Sibenzamine tablets were included in the "National Medical Insurance Catalogue" as a routine second-class management, with the code 932. The scope of medical insurance payment includes patients with relapsed or refractory peripheral T-cell lymphoma. Sibenzamine is the world's first subtype-selective protein deacetylase inhibitor, and has been approved for multiple indications in many regions. The new version of the "National Medical Insurance Catalogue" will be implemented as of January 1, 2026, it is expected that it will not have a significant impact on the company's operating performance for the reporting period.